InsiderTrades

Form 4 for STRO SUTRO BIOPHARMA, INC.

Accepted 2025-05-19 00:00:00 ET · period of report 2025-05-15 · accession 0001415889-25-013618 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-05-19 2025-05-15 STRO ALBINI EDWARD C CFO AND Sec M - OptEx $0.00 +44.7K 176.8K +34% $0
D 2025-05-19 2025-05-15 STRO ALBINI EDWARD C CFO AND Sec F - Tax $0.88 -16.0K 160.8K -9% -$14.1K
DM 2025-05-19 2025-05-15 STRO ALBINI EDWARD C CFO AND Sec M - OptEx $0.00 -44.7K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-05-15 M A 24,438 $0.00 156,519 D — —
2 Common Common Stock 2025-05-15 F D 15,995 $0.88 160,805 D — — (F1) Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
3 Common Common Stock 2025-05-15 M A 11,156 $0.00 167,675 D — —
4 Common Common Stock 2025-05-15 M A 9,125 $0.00 176,800 D — —
5 Derivative Restricted Stock Unit (RSU) 2025-05-15 M D 24,438 $0.00 27,312 D — · — to 2028-03-01 24,438 Common Stock (F2) Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. (F3) The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. (F4) The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025.
6 Derivative Restricted Stock Unit (RSU) 2025-05-15 M D 11,156 $0.00 4,594 D — · — to 2027-03-01 11,156 Common Stock (F2) Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. (F4) The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. (F5) The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
7 Derivative Restricted Stock Unit (RSU) 2025-05-15 M D 9,125 $0.00 0 D — · — to 2026-03-04 9,125 Common Stock (F2) Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. (F4) The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. (F6) The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date.